Sarcoma Research Grant Program

2012 | Jason Cain | Monash | $50,000

Investigating the effect of the histone deacetylase inhibitor, LBH589, on chemotherapy sensitisation and residual disease in pre-clinical models of osteosarcoma

2013 | Jason Cain | Monash | $50,000

Investigating the effect of the histone deacetylase inhibitor, LBH589, on chemotherapy sensitisation and residual disease in pre-clinical models of osteosarcoma

2013-2014 | Susan Neuhaus | Royal Adelaide Hospital | $50,000

Improving outcomes in curable sarcoma

2016 | Christine Hawkins | La Trobe University | $75,000 (over 3 years)

Testing the efficacy and safety of SM-164 for osteosarcoma treatment

2013 | Brendan Joss | Hollywood Private Hospital (WA) | $30,000

A multidisciplinary team approach to improving long term outcomes in sarcoma survivors

2017 | Hayden Snow | Peter MacCallum Cancer Centre | $30,000

Characterising the immune microenvironment in adipocytic and non-adipocytic sarcoma, its impact on prognosis and the effect of radiotherapy

2018 | Jeremy Lewin | Peter MacCallum Cancer Centre | $30,000

Applying radiomics to predict outcomes in patients with high grade retroperitoneal sarcoma treated with preoperative radiotherapy

2019 | Cristina Vargas | Douglass Hanly Moir Pathology, Sonic, and University of Sydney | $40,000

Metastatic and recurrent soft tissue sarcomas – investigation of DNA methylation changes and their contribution to sarcoma progression

2011 | Kate McBride | University of Sydney | $50,000

To map p53 pathway mutations in Australian Sarcoma Kindred Study index cases and examine the relationship with outcomes in these patients

2012 | Mary-Anne Young | Peter MacCallum Cancer Centre | $25,000

Research participants’ and healthcare professionals’ views of the feedback of genetic test information following participation in the International Sarcoma Kindred study (ISKS)

2013 | Gillian Mitchell | Peter MacCallum Cancer Centre | $50,000

A pilot surveillance study in Li Fraumeni syndrome

2013 | Damian Myers | St Vincents Melbourne | $25,000

‘Quantum Dots’ with combined structural and functional imaging to investigate osteosarcoma biology and potential therapies.

2014 | Daniel Gough | Monash Institute of Medical Research | $50,000

Defining the role of STAT3 as a tumour suppressor in osteosarcoma

2015 | David Goode | Peter MacCallum Cancer Centre | $50,000

Validating putative novel sarcoma risk genes via targeted DNA sequencing

2016 | Jeremy Hensen | University of New South Wales | $50,000

New drug combination with ATR-CHK1 axis inhibitors for osteosarcoma

2017 | Lucy Coupland | John Curtin School of Medical Research | $50,000

Novel therapies for osteosarcoma: RNA Pol I inhibitors

2018 | Anneke Blackburn | Australian National University | $50,000

Dichloroacetate (DCA) in Osteosarcoma: A non-toxic agent targeting cancer metabolism

2019 | Willem Joost Lesterhuis | Telethon Kids Institute, Centre for Child Health Research, University of Western Australia | $50,000

Local peri-operative immunotherapy for soft tissue sarcoma

2020 | James Blackburn | Garvan Institute of Medical Research | $50,000

Improving fusion gene detection and immune response assessment in sarcoma patients

2013 | Mannu Walia | St Vincents | $34,000

Deciphering the role of cAMP response element binding protein (CREB) in osteosarcoma

2014 | Liliana Endo-Munoz | Diamantina Institute, University of Queensland | $36,000

Defining the role of STAT3 as a tumour suppressor in osteosarcoma

2015 | Christine Hawkins | La Trobe University | $25,000

Pre-clinical evaluation of IAP antagonists in osteosarcoma

2016 | Kenneth Hsu | The Kids Research Institute, The Children’s Hospital at Westmead | $20,000

Developing genetically modified T-cells for the treatment of paediatric tumours

2018 | Jonathan Karpelowsky | Judging a cell by its cover – osteosarcoma circulating tumour cells testing | $20,000

Judging a cell by its cover – osteosarcoma circulating tumour cells testing

2019 | Belinda Kramer | The Kids Research Institute, The Children’s Hospital at Westmead | $20,000

Mass cytometry to characterise sarcoma targeted CAR T cells and inform clinical trial design

2011-2013 | Kathleen Pishas | University of Adelaide | $25,000 (pa)

Treatment of Ewing sarcoma family of tumours through the pharmacological activation of p53

2013-2015 | Xiaochun Wang | University of New South Wales | $25,000 (pa)

Multiple targeted therapies in human sarcomas

2023 | Minh-Son To | Flinders University | $40,000

Improving the radiological evaluation of bone and soft tissue sarcomas with advanced diffusion imaging and artificial intelligence

2011 | Damien Myers | St Vincents Melbourne | $25,000

Suppression of osteosarcoma tumour invasion and metastasis: Monitoring therapeutic outcomes using advanced imaging techniques

2014 | Katheen Pishas | Hanson Institute, University of Adelaide | $20,000

Exploiting a novel therapeutic target in Ewing sarcoma

2014 | Katheen Pishas | Hanson Institute, University of Adelaide | $20,000

Dedifferentiation of MDM2 amplified low-grade liposarcoma: Comparative genomics and transcriptomics to determine the mechanisms of tumour progression and precision targets

2016 | Timothy Chittleborough | Peter MacCallum Cancer Centre | $20,000

Profiling desmoid tumours in FAP patients and exploring new strategies to prevent and treat desmoid tumours using a novel mouse model

2017 | Toby Trahair | Kids Cancer Centre, Sydney Children's Hospital | $26,000

New therapies for ALK-rearranged inflammatory myofibroblastic tumour (IMT) and epithelioid inflammatory myofibroblastic sarcoma (eIMS)

2018 | Federica Saletta | The Children’s Hospital at Westmead | $20,000

Development of liquid biopsy assays to test minimal residual disease in Ewing sarcoma and alveolar rhabdomyosarcoma patients

2019 | Evan Ingley | Harry Perkins Institute of Medical Research | $20,000

Exploiting a novel therapeutic target in Ewing sarcoma

2020 | Rachael Terry | Children’s Cancer Institute | $40,000

New immunotherapy strategies for paediatric rhabdomyosarcomas

2023 | Carolyn Shembrey | Peter MacCallum Cancer Centre | $40,000

Harnessing CRISPR-Cas13 to ablate 'undruggable' sarcoma drivers